Interestingly, combining an anti-RSPO3 antibody (OMP-131R10) with paclitaxel also reduced tumor growth and nuclear β-catenin expression in 8 APC mutant CRC PDX models when compared to monotherapy [23]. The gene discussed is RSPO3; the disease is neoplasm.